In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems-Reference-Cited by-同舟云学术

In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

Published:2020-11-17 Issue:12 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Karlowsky James A.¹²,Hackel Meredith A.¹^ORCID,Bouchillon Samuel K.¹,Sahm Daniel F.¹

Affiliation:

1. IHMA, Schaumburg, Illinois, USA

2. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Abstract

WCK 5222 (cefepime-zidebactam, 2 g + 1g, every 8 h [q8h]) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined the in vitro susceptibility of 1,385 clinical isolates of non-carbapenem-susceptible Enterobacterales , MDR Pseudomonas aeruginosa (also non-carbapenem susceptible), Stenotrophomonas maltophilia , and Burkholderia spp.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01432-20

Reference34 articles.

1. Carbapenemase-Producing Organisms: A Global Scourge

2. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

3. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections

4. Impact on Morbidity, Mortality, and Length of Stay of Hospital-Acquired Infections by Resistant Microorganisms

5. Interplay between β-lactamases and new β-lactamase inhibitors

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Agents Are Coming, and So Is the Resistance;Antibiotics;2024-07-13

2. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

3. Comparison of BD Phoenix and disk diffusion to broth microdilution for determining cefepime susceptibility among carbapenem-resistant Enterobacterales;Journal of Clinical Microbiology;2024-06-12

4. Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222);European Journal of Clinical Microbiology & Infectious Diseases;2024-02-28

5. Reviewing novel treatment options for carbapenem-resistant Enterobacterales;Expert Review of Anti-infective Therapy;2024-01-10